Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation

Bone Marrow Transplantation

Volumn 35, Issue 11, 2005, Pages 1095-1099

  Iravani, M ^a   Mousavi, A ^a   Gholibeikian, S ^a   Bahar, B ^a   Samiee, S ^a   Ashouri, A ^a   Eghbal, L ^a   Ghavamzadeh, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Allogeneic; Cyclosporine; Graft versus host disease; Methotrexate; Thalassemia major

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BETA THALASSEMIA; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIBLING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; BETA-THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; NEUTROPHILS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20044392186     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704935     Document Type: Article

References (20)

1. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia: long term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
2. Rindgen O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipient with acute leukemia is maintained using cyclosporine A combined with methotrexate as prophylaxis. Bone Marrow Transplantation 1996; 18: 921-929.
3. Locatelli F, Bruno B, Zecca M et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
4. Deeg HJ, Spitzer TR, Cottler-Fox M et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplantation 1991; 7: 193-198.
5. Atkinson K, Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplantation 1995; 16: 755-758.
6. Storb R, Deeg HJ, Fisher L et al. Cyclosporine vs methotrexate for GVHD prevention in patients given marrow grafts for leukemia: long term follow-up of 3 controlled trials. Blood 1988; 71: 293-298.
7. Santos G, Tutschka PJ, Brook Meyer R et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease. A randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21-28.
8. Deeg HJ, Storb R, Thomas GD et al. Cyclosporine as prophylaxis for graft versus host disease. A randomized study in patients undergoing BMT for ANLL. Blood 1985; 65: 1325-1334.
9. Ringden O, Klaesson S, Sundberg B et al. Decreased incidence of GVHD and improved survival with MTX combined with CsA compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992; 9: 19-25.
10. Mrsic M, Labar B, Boganic V et al. Combination of CsA and MTX for prophylaxis of aGVHD after allo BMT for leukemia. Bone Marrow Transplant 1990; 6: 137-141.
11. Gluckman G, Horowitz MM, Champlin RG et al. BMT for severe aplastic anemia: influence of conditioning and GVHD prophylaxis regimens on outcome. Blood 1992; 79: 269-275.
12. Storb R, Deeg HJ, Farewell V et al. BMT for severe aplastic anemia: MTX alone compared with a combination of MTX and CsA for prevention of aGVHD. Blood 1986; 68: 119-125.
13. Storb R, Deeg HJ, Whitehead J et al. MTX and CsA compared with CsA alone for prophylaxis of aGVHD after BMT for leukemia. N Eng J Med 1986; 314: 729-735.
14. Storb R, Deeg HJ, Whitehead J et al. BMT for leukemia and aplastic anemia: Two controlled trials of a combination of MTX and CsA vs CsA alone or MTX alone for prophylaxis of aGVHD. Transplant Proc 1987; 19: 2608-2613.
15. Storb R, Deeg HJ, Pepe M et al. MTX and CsA versus CsA alone for prophylaxis of GVHD in patients given HLA-identical marrow grafts for leukemia: Long term follow up of a controlled trial. Blood 1989; 73: 1729-1734.
16. Atkinson K, Downs K, Asby M et al. Clinical correlation with CsA blood levels after allo BMT. An analysis of four different assays. Transplant Proc 1990; 22: 1331-1334.
17. Hunter AG, Bessell GM, Russell NH. Effective prevention of aGVHD following Allo BMT with low leukemic relapse using MTX and therapeutically monitored levels of CsA. Bone Marrow Transplant 1992; 10: 431-434.
18. Bartolomeo PD, Girolamo GD, Olioso P et al. The Pescara experience at allo BMT in thalassemia. Bone Marrow Transplant 1997; 19: 48-53.
19. Zikos P, Van Lint MT, Frassom F et al. Low transplant mortality in allo BMT for AML. A randomized study of low dose cyclosporine versus low dose cyclosporine and low dose methotrexate. Blood 1991; 9: 3503-3508.
20. Marks DI, Hughes TP, Szydlo R et al. HLA identical sibling BMT for CML in first chronic phase influence of GVHD prophylaxis on outcome. Br J Hematol 1992; 81: 383-390.